178 related articles for article (PubMed ID: 29174536)
1. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Ueda K; Masuda A; Fukuda M; Tanaka S; Hosokawa M; Iwakawa S
Drug Metab Pharmacokinet; 2017 Dec; 32(6):301-310. PubMed ID: 29174536
[TBL] [Abstract][Full Text] [Related]
2. Numerical analysis of apparent decitabine uptake in HCT116 cells: Incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation.
Ueda K; Nakamura T; Tanaka S; Hosokawa M; Iwakawa S; Ogawara KI
Drug Metab Pharmacokinet; 2020 Feb; 35(1):124-130. PubMed ID: 31964620
[TBL] [Abstract][Full Text] [Related]
3. Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells.
Ueda K; Hosokawa M; Iwakawa S
Biol Pharm Bull; 2015; 38(8):1113-9. PubMed ID: 26235575
[TBL] [Abstract][Full Text] [Related]
4. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
6. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Stegmann AP; Honders WH; Willemze R; Ruiz van Haperen VW; Landegent JE
Blood; 1995 Mar; 85(5):1188-94. PubMed ID: 7532033
[TBL] [Abstract][Full Text] [Related]
7. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Beauséjour CM; Gagnon J; Primeau M; Momparler RL
Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
[TBL] [Abstract][Full Text] [Related]
9. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
10. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Stegmann AP; Honders MW; Willemze R; Landegent JE
Leukemia; 1995 Jun; 9(6):1032-8. PubMed ID: 7541096
[TBL] [Abstract][Full Text] [Related]
11. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
[TBL] [Abstract][Full Text] [Related]
12. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
Damaraju VL; Mowles D; Yao S; Ng A; Young JD; Cass CE; Tong Z
Nucleosides Nucleotides Nucleic Acids; 2012; 31(3):236-55. PubMed ID: 22356238
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.
Hosokawa M; Saito M; Nakano A; Iwashita S; Ishizaka A; Ueda K; Iwakawa S
Oncol Lett; 2015 Aug; 10(2):761-767. PubMed ID: 26622566
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
[TBL] [Abstract][Full Text] [Related]
16. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
